The European Medicines Agency's Committee For Medicinal Products For Human Use Adopted A Positive Opinion Recommending Marketing Authorization Of Moderna's mNEXSPIKE (mRNA-1283), New Covid Vaccine For Individuals Aged 12 Years And Older

Benzinga · 2d ago
  • mNEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine)
  • mNEXSPIKE will be available in the European Union, subject to authorization by the European Commission